Advances in Clinical Chemistry, Volume 133 in this ongoing series, examines physiologic and pathophysiologic biochemistry and their impacts on Clinical Chemistry testing and design. Molecular mechanisms of disease processes are highlighted in the context of traditional, current, and emerging technologies, and advances in the development of improved diagnostic and predictive biomarkers are examined, especially those targeting early and emerging diseases. Specific chapters in this new release include Drug Induced Renal Injury (DIRI) Biomarkers, Unveiling tobacco markers in exhaled breath, Advances in small extracellular vesicle analysis, Piezoelectric Sensors in Point-of-Care Testing, Mitochondrial myopathy biomarkers, and Hormonal and Metabolic Biomarkers in Long COVID.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
1. Drug Induced Renal Injury (DIRI) BiomarkersEmina Karahmet Sher
2. Unveiling tobacco markers in exhaled breath
Agapios Agapiou
3. Advances in small extracellular vesicle analysis
Wei Zhang
4. Piezoelectric Sensors in Point-of-Care Testing
Miroslav Pohanka
5. Mitochondrial myopathy biomarkers
Roberto Scatena
6. Hormonal and Metabolic Biomarkers in Long COVID
M Dalamaga
